Resveratrol Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Patients With Type 2 Diabetes Mellitus

Access this Article

Search this Article

Author(s)

    • Imamura Haruki
    • Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center
    • Yamaguchi Takashi
    • Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center
    • Nagayama Daiji
    • Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center
    • Saiki Atsuhito
    • Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center
    • Shirai Kohji
    • Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center
    • Tatsuno Ichiro
    • Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center

Abstract

<p>Resveratrol has been reported to have potent anti-atherosclerotic effects in animal studies. However, there are few interventional studies in human patients with atherosclerogenic diseases. The cardio-ankle vascular index (CAVI) reflects arterial stiffness and is a clinical surrogate marker of atherosclerosis. The aim of the present study was to investigate the effect of resveratrol on arterial stiffness assessed by CAVI in patients with type 2 diabetes mellitus (T2DM).</p><p>In this double-blind, randomized, placebo-controlled study, 50 patients with T2DM received supplement of a 100mg resveratrol tablet (total resveratrol: oligo-stilbene 27.97 mg/100 mg/day) or placebo daily for 12 weeks. CAVI was assessed at baseline and the end of study. Body weight (BW), blood pressure (BP), glucose and lipid metabolic parameters, and diacron-reactive oxygen metabolites (d-ROMs; an oxidative stress marker) were also measured.</p><p>Resveratrol supplementation decreased systolic BP (-5.5 ± 13.0 mmHg), d-ROMs (-25.6 ± 41.8 U.CARR), and CAVI (-0.4 ± 0.7) significantly (<i>P</i> < 0.05) and decreased BW (-0.8 ± 2.1 kg, <i>P</i> = 0.083) and body mass index (-0.5 ± 0.8 kg/m<sup>2</sup>, <i>P</i> = 0.092) slightly compared to baseline, while there were no significant changes in the placebo group. Decreases in CAVI and d-ROMs were significantly greater in the resveratrol group than in the placebo group. Multivariate logistic regression analysis identified resveratrol supplementation as an independent predictor for a CAVI decrease of more than 0.5.</p><p>In conclusion, 12-week resveratrol supplementation may improve arterial stiffness and reduce oxidative stress in patients with T2DM. Resveratrol may be beneficial in preventing the development of atherosclerosis induced by diabetes. However, a large-scale cohort study is required to validate the present findings.</p>

Journal

  • International Heart Journal

    International Heart Journal 58(4), 577-583, 2017

    International Heart Journal Association

Codes

  • NII Article ID (NAID)
    130005901303
  • Text Lang
    ENG
  • ISSN
    1349-2365
  • Data Source
    J-STAGE 
Page Top